Estimating individualized treatment effects from randomized controlled trials: a simulation study to compare risk-based approaches - PubMed
- ️Sun Jan 01 2023
Estimating individualized treatment effects from randomized controlled trials: a simulation study to compare risk-based approaches
Alexandros Rekkas et al. BMC Med Res Methodol. 2023.
Abstract
Background: Baseline outcome risk can be an important determinant of absolute treatment benefit and has been used in guidelines for "personalizing" medical decisions. We compared easily applicable risk-based methods for optimal prediction of individualized treatment effects.
Methods: We simulated RCT data using diverse assumptions for the average treatment effect, a baseline prognostic index of risk, the shape of its interaction with treatment (none, linear, quadratic or non-monotonic), and the magnitude of treatment-related harms (none or constant independent of the prognostic index). We predicted absolute benefit using: models with a constant relative treatment effect; stratification in quarters of the prognostic index; models including a linear interaction of treatment with the prognostic index; models including an interaction of treatment with a restricted cubic spline transformation of the prognostic index; an adaptive approach using Akaike's Information Criterion. We evaluated predictive performance using root mean squared error and measures of discrimination and calibration for benefit.
Results: The linear-interaction model displayed optimal or close-to-optimal performance across many simulation scenarios with moderate sample size (N = 4,250; ~ 785 events). The restricted cubic splines model was optimal for strong non-linear deviations from a constant treatment effect, particularly when sample size was larger (N = 17,000). The adaptive approach also required larger sample sizes. These findings were illustrated in the GUSTO-I trial.
Conclusions: An interaction between baseline risk and treatment assignment should be considered to improve treatment effect predictions.
Keywords: Absolute benefit; Prediction models; Treatment effect heterogeneity.
© 2023. The Author(s).
Conflict of interest statement
A.R. and P.R.R. work for a research group that received/receives unconditional research grants from Yamanouchi, Pfizer-Boehringer Ingelheim, Novartis, GSK, Chiesi, Astra-Zeneca, Amgen, Janssen Research & Development. None of these relate to the content of this paper. The remaining authors have disclosed that they do not have any potential conflicts of interest.
Figures

RMSE of the considered methods across 500 replications was calculated from a simulated super-population of size 500,000. The scenario with true constant relative treatment effect (panel A) had a true prediction c-statistic of 0.75 and sample size of 4250. The RMSE is also presented for strong linear (panel B), strong quadratic (panel C), and non-monotonic (panel D) deviations from constant relative treatment effects. Panels on the right side present the true relations between baseline risk (x-axis) and absolute treatment benefit (y-axis). The 2.5, 25, 50, 75, and 97.5 percentiles of the risk distribution are expressed by the boxplot on the top. The 2.5, 25, 50, 75, and 97.5 percentiles of the true benefit distributions are expressed by the boxplots on the side of the right-handside panel

RMSE of the considered methods across 500 replications calculated in simulated samples of size 17,000 rather than 4,250 in Fig. 1. RMSE was calculated on a super-population of size 500,000

RMSE of the considered methods across 500 replications calculated in simulated samples 4,250. True prediction c-statistic of 0.85. RMSE was calculated on a super-population of size 500,000

Discrimination for benefit of the considered methods across 500 replications calculated in simulated samples of size 4,250 using the c-statistic for benefit. The c-statistic for benefit represents the probability that from two randomly chosen matched patient pairs with unequal observed benefit, the pair with greater observed benefit also has a higher predicted benefit. True prediction c-statistic of 0.75

Calibration for benefit of the considered methods across 500 replications calculated in a simulated sample of size 500,000. True prediction c-statistic of 0.75 and sample size of 4,250

Individualized absolute benefit predictions based on baseline risk when using a constant treatment effect approach, a linear interaction approach and RCS smoothing using 3 knots. Risk stratified estimates of absolute benefit are presented within quartiles of baseline risk as reference. 95% confidence bands were generated using 10,000 bootstrap resamples, where the prediction model was refitted in each run to capture the uncertainty in baseline risk predictions. For the risk stratification approach, we also provide 95% confidence intervals for the baseline risk quarter-specific average predicted risk over the 10,000 bootstrap samples
Similar articles
-
Crider K, Williams J, Qi YP, Gutman J, Yeung L, Mai C, Finkelstain J, Mehta S, Pons-Duran C, Menéndez C, Moraleda C, Rogers L, Daniels K, Green P. Crider K, et al. Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217. Cochrane Database Syst Rev. 2022. PMID: 36321557 Free PMC article.
-
van Klaveren D, Balan TA, Steyerberg EW, Kent DM. van Klaveren D, et al. J Clin Epidemiol. 2019 Oct;114:72-83. doi: 10.1016/j.jclinepi.2019.05.029. Epub 2019 Jun 10. J Clin Epidemiol. 2019. PMID: 31195109 Free PMC article.
-
Brookes ST, Whitley E, Peters TJ, Mulheran PA, Egger M, Davey Smith G. Brookes ST, et al. Health Technol Assess. 2001;5(33):1-56. doi: 10.3310/hta5330. Health Technol Assess. 2001. PMID: 11701102 Review.
-
Performance metrics for models designed to predict treatment effect.
Maas CCHM, Kent DM, Hughes MC, Dekker R, Lingsma HF, van Klaveren D. Maas CCHM, et al. BMC Med Res Methodol. 2023 Jul 8;23(1):165. doi: 10.1186/s12874-023-01974-w. BMC Med Res Methodol. 2023. PMID: 37422647 Free PMC article.
-
Lin JS, Evans CV, Johnson E, Redmond N, Burda BU, Coppola EL, Smith N. Lin JS, et al. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Jul. Report No.: 17-05225-EF-1. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Jul. Report No.: 17-05225-EF-1. PMID: 30234933 Free Books & Documents. Review.
Cited by
-
Selby JV, Maas CCHM, Fireman BH, Kent DM. Selby JV, et al. medRxiv [Preprint]. 2025 Feb 21:2024.05.06.24306774. doi: 10.1101/2024.05.06.24306774. medRxiv. 2025. PMID: 38766150 Free PMC article. Preprint.
-
Jacquemyn X, Van den Eynde J, Chinni BK, Danford DM, Kutty S, Manlhiot C. Jacquemyn X, et al. J Am Med Inform Assoc. 2024 Aug 1;31(8):1704-1713. doi: 10.1093/jamia/ocae136. J Am Med Inform Assoc. 2024. PMID: 38900193
References
-
- Wager S, Athey S. Estimation and Inference of Heterogeneous Treatment Effects using Random Forests. J Am Stat Assoc. 2018;113:1228–1242. doi: 10.1080/01621459.2017.1319839. - DOI
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources